RaQualia Pharma (TSE:4579) Change In Receivables: 円-55 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSE:4579 RaQualia Pharma Inc TSE:4579
58 GF Score
Price 円566.00
GF Value 円748.44
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is RaQualia Pharma Change In Receivables?

RaQualia Pharma TSE:4579 -1.22% 58 Change In Receivables is 円-55 Mil as of Jun. 2026. GuruFocus rates TSE:4579 with a GF Score™ of 58/100 and a GF Value™ of 円748.44 (Modestly Undervalued). The stock has 3 warning signs investors should review.

RaQualia Pharma's change in receivables for the quarter that ended in Jun. 2026 was 円0 Mil. It means RaQualia Pharma's Accounts Receivable stayed the same from Mar. 2026 to Jun. 2026 .

RaQualia Pharma's change in receivables for the fiscal year that ended in Dec. 2025 was 円-1,220 Mil. It means RaQualia Pharma's Accounts Receivable increased by 円1,220 Mil from Dec. 2024 to Dec. 2025 .

RaQualia Pharma's Accounts Receivable for the quarter that ended in Jun. 2026 was 円852 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. RaQualia Pharma's liquidation value for the three months ended in Jun. 2026 was 円2,242 Mil.

RaQualia Pharma  (TSE:4579) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

RaQualia Pharma's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=852.358/0*91
=

2. In Ben Graham's calculation of liquidation value, RaQualia Pharma's accounts receivable are only considered to be worth 75% of book value:

RaQualia Pharma's liquidation value for the quarter that ended in Jun. 2026 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=4696.315-3175.698+0.75 * 852.358+0.5 * 164.202
=2,242

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Change In Receivables Related Terms

RaQualia Pharma Change In Receivables Historical Data

* Premium members only.

The historical data trend for RaQualia Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RaQualia Pharma Change In Receivables Chart

RaQualia Pharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only -598.70 579.06 -92.33 -11.82 -1,219.57

RaQualia Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 529.33 107.03 -1,359.47 668.33 0.00
TSE:4579
58GF Score
RaQualia Pharma Inc TSE:4579
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RaQualia Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was 円-55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of 円-55 Mil mean?
RaQualia Pharma (TSE:4579) has a Change In Receivables of 円-55 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for RaQualia Pharma and its competitors.
Is RaQualia Pharma's Change In Receivables too high?
RaQualia Pharma's current Change In Receivables is 円-55 Mil. Overall, RaQualia Pharma has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does RaQualia Pharma's Change In Receivables compare to VRTX and REGN?
RaQualia Pharma's Change In Receivables of 円-55 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Biotechnology company?
A good Change In Receivables depends on the Biotechnology industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for RaQualia Pharma and its competitors. RaQualia Pharma's current Change In Receivables is 円-55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RaQualia Pharma stock overvalued right now?
Based on GuruFocus' analysis, RaQualia Pharma (TSE:4579) is currently considered Modestly Undervalued. The stock's GF Value™ is 円748.44, compared to a current price of 円566.00 — trading 24.4% below its estimated fair value. The current Change In Receivables is 円-55 Mil. RaQualia Pharma's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For RaQualia Pharma (TSE:4579), the current Change In Receivables is 円-55 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is RaQualia Pharma (TSE:4579) Overvalued in 2026?

Based on GuruFocus' analysis, RaQualia Pharma stock appears to be undervalued. The current stock price of 円566.00 is trading 24.4% below its estimated GF Value™ of 円748.44. GuruFocus considers RaQualia Pharma to be Modestly Undervalued.

Key valuation signals for TSE:4579:

  • Change In Receivables: 円-55 Mil
  • GF Value™: 円748.44 vs. price of 円566.00 (24.4% below fair value)
  • GF Score™: 58/100 with 3 warning signs

No single metric tells the full story. See the TSE:4579 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

RaQualia Pharma Business Description

Address 1-21-19 Meieki Minami, Nakamura-ku, Nagoya, JPN, 470-2341
RaQualia Pharma Inc operates as a research and development-centered biotechnology company, generating revenue by creating the seeds for novel medicine and licensing them to pharmaceutical companies. The company manages the Sales and licensing of intellectual property for fundamental technologies related to pharmaceutical compounds and candidate compounds for clinical development. Its product portfolio includes, Tegoprazan (K-CAB), Galliprant and Elura both under Veterinary Medicines. The pipeline products include Potassium-Competitive Acid Blocker, Ghrelin Receptor Agonist, TRPM8 Blocker and 5-HT4 Agonist studied under different phases of development.
58GF Score

Get the complete analysis for TSE:4579

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円566.00
Price
円748.44
GF Value